REVIEW ARTICLE
Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disease
Sarah Healy,
Kariem Tarik Elhadd,
Emily Gibbons,
Dan Whittam,
Michael Griffiths,
Anu Jacob,
Saif Huda,
Corresponding Author
Sarah Healy
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Correspondence
Sarah Healy, Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
Email: [email protected]
Search for more papers by this authorKariem Tarik Elhadd
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorEmily Gibbons
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorDan Whittam
Department of Neurology, Salford Royal NHS Foundation Trust, Manchester, UK
Search for more papers by this authorMichael Griffiths
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
Search for more papers by this authorAnu Jacob
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Department of Neurology, Cleveland Clinic, Abu Dhabi, United Arab Emirates
Search for more papers by this authorSaif Huda
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorSarah Healy,
Kariem Tarik Elhadd,
Emily Gibbons,
Dan Whittam,
Michael Griffiths,
Anu Jacob,
Saif Huda,
Corresponding Author
Sarah Healy
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Correspondence
Sarah Healy, Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.
Email: [email protected]
Search for more papers by this authorKariem Tarik Elhadd
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorEmily Gibbons
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorDan Whittam
Department of Neurology, Salford Royal NHS Foundation Trust, Manchester, UK
Search for more papers by this authorMichael Griffiths
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
Search for more papers by this authorAnu Jacob
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Department of Neurology, Cleveland Clinic, Abu Dhabi, United Arab Emirates
Search for more papers by this authorSaif Huda
Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
Search for more papers by this authorAbstract
Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disease (MOGAD) is increasingly recognized as a distinct nosological entity from aquaporin-4 antibody IgG–positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD). The advent of highly specific MOG-IgG cell-based diagnostic assays have helped to refine our understanding of the clinical spectrum of MOGAD. To date, treatment approaches have been largely extrapolated from AQP4-IgG NMOSD experience, but there is growing evidence of distinct differences in treatment response between these conditions. This review summarizes the current status and understanding of acute and chronic treatments for MOGAD. Timing and duration of treatment, pregnancy, and emerging therapies are also discussed.
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.
REFERENCES
- 1Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology Neuroimmunol Neuroinflammation. 2015; 2(3): e89. https://doi.org/10.1212/nxi.0000000000000089
- 2Hjelmström P, Penzotti JE, Henne RM, Lybrand TP. A molecular model of myelin oligodendrocyte glycoprotein. J Neurochem. 1998; 71(4): 1742–9. https://doi.org/10.1046/j.1471-4159.1998.71041742.x
- 3Johns TG, Bernard CCA. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999; 72(1): 1–9. https://doi.org/10.1046/j.1471-4159.1999.0720001.x
- 4Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020; 143(5): 1431–46. https://doi.org/10.1093/brain/awaa102
- 5Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathologica Commun. 2014; 2(1): 35. https://doi.org/10.1186/2051-5960-2-35
- 6Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-Encephalomyelitis. Front Neurol. 2018; 9: 888. https://doi.org/10.3389/fneur.2018.00888
- 7Prasad S, Chen J. What You Need to Know About AQP4, MOG, and NMOSD. Semin Neurol. 2019; 39(06): 718–31. https://doi.org/10.1055/s-0039-3399505
- 8Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. Jama Neurol. 2017; 75(1): 65. https://doi.org/10.1001/jamaneurol.2017.3196
- 9Cobo-Calvo Á, Ruiz A, D’Indy H, Poulat A-L, Carneiro M, Philippe N, et al. MOG antibody-related disorders: common features and uncommon presentations. J Neurol. 2017; 264(9): 1945–55. https://doi.org/10.1007/s00415-017-8583-z
- 10Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–89. https://doi.org/10.1212/wnl.0000000000001729
- 11Zhang W, Cui L, Zhang Y, Wang W, Wang R, Liu Z, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. J Neurol. 2020; 267(4): 1197–205. https://doi.org/10.1007/s00415-019-09685-3
- 12Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020; 267(12): 3565–3577. https://doi.org/10.1007/s00415-020-10026-y
- 13Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016; 13(1): 280. https://doi.org/10.1186/s12974-016-0718-0
- 14Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017; 140(12): 3128–38. https://doi.org/10.1093/brain/awx276
- 15Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology. 2018; 90(21): e1858–e1869. https://doi.org/10.1212/wnl.0000000000005560
- 16Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflamm. 2019; 16(1): 134. https://doi.org/10.1186/s12974-019-1525-1
- 17Zhuo Z, Duan Y, Tian D, Wang X, Gao C, Ding J, et al. Brain structural and functional alterations in MOG antibody disease. Mult Scler J. 2020; 135245852096441. Epub ahead of print. https://doi.org/10.1177/1352458520964415
- 18Bonnan M, Valentino R, Debeugny S, Merle H, Fergé J-L, Mehdaoui H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurology Neurosurg Psychiatry. 2018; 89(4): 346. https://doi.org/10.1136/jnnp-2017-316286
- 19Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga AS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020; 95(2): e111–20. https://doi.org/10.1212/WNL.0000000000009758
- 20Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016; 15(4): 307–24. https://doi.org/10.1016/j.autrev.2015.12.004
- 21Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017; 264(10): 2088–94. https://doi.org/10.1007/s00415-017-8596-7
- 22Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMdH, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82(6): 474–81. https://doi.org/10.1212/wnl.0000000000000101
- 23Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, et al. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. J Neurol Sci. 2017; 4: 240–4. https://www.jns-journal.com/article/S0022-510X(17)33755-3/fulltext
- 24Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial. Jama Ophthalmol. 2018; 136(4): 419. https://doi.org/10.1001/jamaophthalmol.2017.6757
- 25Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018; 89(2): 127. https://doi.org/10.1136/jnnp-2017-316880
- 26Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study. JAMA Neurol. 2014; 71(3): 276–83. https://doi.org/10.1001/jamaneurol.2013.5857
- 27Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018; 75(4): 478–87. https://pubmed.ncbi.nlm.nih.gov/29305608
- 28Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Dis. 2020; 44: 102251. https://doi.org/10.1016/j.msard.2020.102251
- 29Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol. 2019; 266(5): 1280–6. https://doi.org/10.1007/s00415-018-9122-2
- 30Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Option Neurol. 2019; 21(1): 2. https://doi.org/10.1007/s11940-019-0541-x
- 31Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids. JAMA Neurol. 2018; 75(6): 690. https://jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2018.0024&appId=scweb
- 32Segamarchi C, Silva B, Saidon P, Garcea O, Alonso R. Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes. Mult Scler Relat Dis. 2020; 46: 102449. https://doi.org/10.1016/j.msard.2020.102449
- 33Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflammation. 2019; 6(4): e572. https://doi.org/10.1212/nxi.0000000000000572
- 34Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014; 261(1): 1–16. https://doi.org/10.1007/s00415-013-7169-7
- 35Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016; 79(2): 206–16. https://doi.org/10.1002/ana.24554
- 36Banerjee A, Ng J, Coleman J, Ospina JP, Mealy M, Levy M. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Dis. 2018; 28: 60–3. https://doi.org/10.1016/j.msard.2018.12.010
- 37Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol. 2020; 20(2): 92. https://doi.org/10.1136/practneurol-2019-002336
- 38Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve. 2013; 47(4): 510–4. https://doi.org/10.1002/mus.23626
- 39Oji S, Nomura K. Immunoadsorption in neurological disorders. Transfus Apheres Sci. 2017. https://www.trasci.com/article/S1473-0502(17)30164-7/fulltext
- 40Koziolek MJ, Tampe D, Bähr M, Dihazi H, Jung K, Fitzner D, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflamm. 2012; 9(1): 80. https://doi.org/10.1186/1742-2094-9-80
- 41Levy M. Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018; 5(6): e510. https://doi.org/10.1212/nxi.0000000000000510
- 42Dourmishev LA, Guleva DV, Miteva LG. Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses. Int J Inflamm. 2016; 2016: 1–6. https://doi.org/10.1155/2016/3523057
- 43Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler J. 2013; 20(4): 501–4. https://doi.org/10.1177/1352458513495938
- 44Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, et al. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technol Asses. 2017; 21(31): 1–50. https://doi.org/10.3310/hta21310
- 45Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurol J Am Hear Assoc. 2002; 58(1): 143–6. https://doi.org/10.1212/wnl.58.1.143
- 46Llufriu S, Castillo J, Blanco Y, Ramio-Torrenta L, Rio J, Valles M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology. 2009; 73(12): 949–53. https://doi.org/10.1212/wnl.0b013e3181b879be
- 47Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46(6): 878–86. https://doi.org/10.1002/1531-8249(199912)46:6<878:aid-ana10>3.0.co;2-q
- 48Meca-Lallana JE, Hernández-Clares R, León-Hernández A, Aleixandre AG, Pérez MC, Martín-Fernández JJ. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study. Clin Ther. 2013; 35(4): 474–85. https://doi.org/10.1016/j.clinthera.2013.02.027
- 49Magaña SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011; 68(7): 870–8. https://doi.org/10.1001/archneurol.2011.34
- 50Kim S-H, Kim W, Huh S-Y, Lee KY, Jung IJ, Kim HJ. Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels. J Clin Neurol. 2012; 9(1): 36–42. https://doi.org/10.3988/jcn.2013.9.1.36
- 51Soelberg K, Specovius S, Zimmermann HG, Grauslund J, Mehlsen JJ, Olesen C, et al. Optical coherence tomography in acute optic neuritis: a population-based study. Acta Neurol Scand. 2018; 138(6): 566–73. https://doi.org/10.1111/ane.13004
- 52Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011; 78(11): 748–56. https://pubmed.ncbi.nlm.nih.gov/22049542/
- 53Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists’ management guidelines. Pract Neurol. 2015; 15(3): 199. https://doi.org/10.1136/practneurol-2015-001126
- 54Lippuner K, Casez J-P, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients 1. J Clin Endocrinol Metab. 1998; 83(11): 3795–802. https://doi.org/10.1210/jcem.83.11.5235
- 55McWilliam M, Khan U. Azathioprine and the neurologist. Pract. Neurol. 2020; 20(1): 69. https://doi.org/10.1136/practneurol-2018-002161
- 56Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A, et al. Neuromyelitis optica spectrum disorders. Clin Med. 2019; 19(2): 169–76. https://doi.org/10.7861/clinmedicine.19-2-169
- 57Nagy F, Molnár T, Szepes Z, Farkas K, Nyári T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol. 2008; 14(27): 4342–6. https://doi.org/10.3748/wjg.14.4342
- 58Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017; 24(1): 219–26. https://doi.org/10.1111/ene.13186
- 59Yang Y, Wang C, Wang B, Zeng Z, Guo S. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018; 385: 192–7. https://doi.org/10.1016/j.jns.2017.12.034
- 60Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3): e705. https://doi.org/10.1212/nxi.0000000000000705
- 61Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020; 19(4): 298–306. https://doi.org/10.1016/s1474-4422(20)30066-1
- 62Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016; 73(11): 1342. https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2016.1637
- 63Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68(11): 1412–20. https://doi.org/10.1001/archneurol.2011.154
- 64Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019; 19(1): 5. https://doi.org/10.1136/practneurol-2018-001899
- 65Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018; 265(5): 1115–22. https://doi.org/10.1007/s00415-018-8812-0
- 66Nakashima I, Takahashi T, Cree BAC, Kim HJ, Suzuki C, Genain CP, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011; 18(7): 997–8. https://doi.org/10.1016/j.jocn.2010.12.011
- 67Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015; 2(1): e61. https://doi.org/10.1212/nxi.0000000000000061
- 68Choi S-J, Kim B, Lee H-J, Kim S-J, Kim S-M, Sung J-J. Rebound of relapses after discontinuation of rituximab in a patient with MOG-IgG1 positive highly relapsing optic neuritis: a case report. BMC Neurol. 2018; 18(1): 216. https://doi.org/10.1186/s12883-018-1222-1
- 69Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019; 19(1): 36. https://doi.org/10.1186/s12883-019-1261-2
- 70Christou EAA, Giardino G, Worth A, Ladomenou F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol. 2017; 36(6): 1–8. https://doi.org/10.1080/08830185.2017.1346092
- 71Tsantes E, Curti E, Siena E, Granella F. SUCCESSFUL INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN RELAPSING MOG-ANTIBODY-ASSOCIATED DISEASE. Mult Scler Relat Dis. 2019; 32: 27–9. https://doi.org/10.1016/j.msard.2019.04.021
- 72Domingo-Santos Á, Sepúlveda M, Matarazzo M, Calleja-Castaño P, Ramos-González A, Saiz A, et al. Intravenous Immunoglobulin Therapy in a Patient With Anti-Myelin Oligodendrocyte Glycoprotein-Seropositive Neuromyelitis Optica. Clin Neuropharmacol. 2016; 39(6): 332–4. https://doi.org/10.1097/wnf.0000000000000176
- 73Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013; 84(8): 918. https://doi.org/10.1136/jnnp-2012-304774
- 74Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, et al. Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder. Intern Med. 2013; 52(9): 969–72. https://doi.org/10.2169/internalmedicine.52.7885
- 75Bichuetti DB, Oliveira EML, de Boulos FC, Gabbai AA. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol. 2012; 69(7): 938–9. https://doi.org/10.1001/archneurol.2012.545
- 76Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015; 351(1–2): 31–5. https://doi.org/10.1016/j.jns.2015.02.012
- 77Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014; 82(15): 1302–6. https://doi.org/10.1212/wnl.0000000000000317
- 78Ringelstein M, Ayzenberg I, Harmel J, Lauenstein A-S, Lensch E, Stögbauer F, et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015; 72(7): 756–63. https://doi.org/10.1001/jamaneurol.2015.0533
- 79Hayward-Koennecke H, Reindl M, Martin R, Schippling S. Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology. 2019; 92(16): 765–7. https://doi.org/10.1212/wnl.0000000000007312
- 80Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurology. 2020; 19(5): 391–401. https://doi.org/10.1016/s1474-4422(20)30070-3
- 81Novi G, Gastaldi M, Franciotta D, Pesce G, Benedetti L, Uccelli A. Tocilizumab in MOG-antibody spectrum disorder: a case report. Mult Scler Relat Dis. 2018; 27: 312–4. https://doi.org/10.1016/j.msard.2018.11.012
- 82Rigal J, Pugnet G, Ciron J, Lépine Z, Biotti D. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Dis. 2020; 46: 102483. https://doi.org/10.1016/j.msard.2020.102483
- 83Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmun Highlights. 2017; 8(1): 12. https://doi.org/10.1007/s13317-017-0100-y
- 84Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016; 263(1): 25–9. https://doi.org/10.1007/s00415-015-7925-y
- 85Otto F, Moser T, Feige J, Seiberl M, Bieler L, Sellner J. Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. Mult Scler Relat Dis. 2020; 42: 102108. https://doi.org/10.1016/j.msard.2020.102108
- 86Ellis R, Brown S, Boggild M. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? Mult Scler J. 2014; 21(5): 642–5. https://doi.org/10.1177/1352458514541508
- 87Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013; 84(5): 511. https://doi.org/10.1136/jnnp-2012-303121
- 88Wingerchuk DM. Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary. Mult Scler J. 2019; 25(9): 1220–2. https://doi.org/10.1177/1352458519837924
- 89Hyun J-W, Woodhall MR, Kim S-H, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017; 88(10): 811. https://doi.org/10.1136/jnnp-2017-315998
- 90Woodhall M, Mitchell JW, Gibbons E, Healy S, Waters P, Huda S. Case report: myelin oligodendrocyte glycoprotein antibody-associated relapse with COVID-19. Front Neurol. 2020; 11: 598531. https://doi.org/10.3389/fneur.2020.598531
- 91Juryńczyk M, Jacob A, Fujihara K, Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract Neurol. 2019; 19(3): 187. https://doi.org/10.1136/practneurol-2017-001787
- 92Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021; 89(1): 30–41. https://doi.org/10.1002/ana.25909
- 93Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020; 16(3): 154–70. https://doi.org/10.1038/s41582-020-0313-y
- 94Rego CAD, Collongues N, Bourre B, Biotti D, Marignier R, Maillart E, et al. Disease activity during pregnancy in patients with AQP4-Ab positive, MOG-Ab positive or double negative NMOSD. Mult Scler. 2018; 24: 541. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228826/cecilia.alves.do.rego.disease.activity.during.pregnancy.in.patients.with.html
- 95Zhang Y, Li D, Guo H, Wang W, Li X, Shen S. Association between thiopurines use and pregnancy outcomes in female patients with inflammatory bowel disease: a meta-analysis. Curr Pharm Des. 2020. https://pubmed.ncbi.nlm.nih.gov/32938343/
- 96Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003; 52(2): 243. https://doi.org/10.1136/gut.52.2.243
- 97Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003; 124(1): 9–17. https://doi.org/10.1053/gast.2003.50014
- 98Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, et al. The effect on the fetus of medications used to treat pregnant inflammatory Bowel-Disease patients. Am J Gastroenterol. 2004; 99(4): 656–61. https://doi.org/10.1111/j.1572-0241.2004.04140.x
- 99Coelho J, Beaugerie L, Colombel JF, Hebuterne X, Lerebours E, Lemann M, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011; 60(2): 198. https://doi.org/10.1136/gut.2010.222893
- 100Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 19(1): 15–22. https://doi.org/10.1002/ibd.22948
- 101Naqvi R, Noor H, Ambareen S, Khan H, Haider A, Jafri N, et al. Outcome of pregnancy in renal allograft recipients: SIUT experience. Transplant Proc. 2006; 38(7): 2001–2. https://doi.org/10.1016/j.transproceed.2006.06.020
- 102 Mylan. Azathioprine tablets 50mg. emc. 2017. https://www.medicines.org.uk/emc/product/2541/smpc#gref
- 103Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. Can Med Assoc J. 2011; 183(7): 796–804. https://doi.org/10.1503/cmaj.101063
- 104Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res Part Clin Mol Teratol. 2014; 100(6): 499–506. https://doi.org/10.1002/bdra.23248
- 105Bandoli G, Palmsten K, Smith CJF, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin N Am. 2017; 43(3): 489–502. https://doi.org/10.1016/j.rdc.2017.04.013
- 106Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018; 5(3): e453. https://doi.org/10.1212/nxi.0000000000000453
- 107Krysko KM, LaHue SC, Anderson A, Rutatangwa A, Rowles W, Schubert RD, et al. Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions. Neurol Neuroimmunol Neuroinflamm. 2020; 7(1): e637. https://doi.org/10.1212/nxi.0000000000000637
- 108Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007; 6(4): 257–9. https://doi.org/10.1016/j.autrev.2006.08.011
- 109Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apheresis. 2017; 32(3): 191–5. https://doi.org/10.1002/jca.21468
- 110Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. New Engl J Med. 2019; 381(7): 614–25. https://doi.org/10.1056/nejmoa1900866
- 111Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. New Engl J Med. 2019; 381(22): 2114–24. https://doi.org/10.1056/nejmoa1901747
- 112Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019; 394(10206): 1352–63. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31817-3/fulltext
- 113Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, et al. Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020; 77(1): 82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763982/
- 114Zuckner J, Uddin J, Ramsey RH. Intramuscular Administration of Steroids in Treatment of Rheumatoid Arthritis. Ann Rheum Dis. 1964; 23(6): 456. https://doi.org/10.1136/ard.23.6.456
- 115Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. Indian J Endocrinol Metabolism. 2013; 17(9): 612–7. https://doi.org/10.4103/2230-8210.123548
10.4103/2230?8210.123548 Google Scholar
- 116Noland DK, Greenberg BM. Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurol Clin Pract. 2018; 8(4): 327–30. https://doi.org/10.1212/cpj.0000000000000480
- 117Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66(9): 1128–33. https://doi.org/10.1001/archneurol.2009.175
- 118Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler J. 2016; 23(10): 1377–84. https://doi.org/10.1177/1352458516678474
- 119Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K. Group for the HKNS. Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J Am Soc Nephrol. 2005; 16(4): 1076–84. https://doi.org/10.1681/asn.2004080686
- 120Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114(2): 154–63. https://doi.org/10.1016/j.clim.2004.09.001
- 121Busger op Vollenbroek FTM, Doggen CJM, Janssens RWA, Bernelot Moens HJ. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS One. 2018; 13(3):e0194401. https://doi.org/10.1371/journal.pone.0194401
- 122Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol. 2018; 174(4): 255–64. https://doi.org/10.1016/j.neurol.2017.11.005
- 123Kim S-H, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica. Arch Neurol. 2011; 68(4): 473–9. https://doi.org/10.1001/archneurol.2010.322
- 124Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New Engl J Med. 2020; 383(6): 546–57. https://doi.org/10.1056/nejmoa1917246
- 125 NHS.net. Prednisolone. 2019. https://www.nhs.uk/medicines/prednisolone/
- 126Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol. 1997; 176(1): 241–53. https://doi.org/10.1016/s0002-9378(97)80043-9
- 127Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005; 121(2): 129–38. https://doi.org/10.1016/j.ejogrb.2005.01.002
- 128Ford SF, Sketris IS, Jones JV. Are oral contraceptives removed during plasmapheresis? Transfus Sci. 1991; 12(1–2): 87–90. https://doi.org/10.1016/0955-3886(91)90017-w
10.1016/0955?3886(91)90017?w Google Scholar
- 129Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian J Pharmacol. 2018; 6: 302–8. https://www.ijp-online.com/article.asp?issn=0253-7613;year=2018;volume=50;issue=6;spage=302;epage=308;aulast=Bansal
- 130Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis Executive summary. Neurology. 2016; 87(4): 419–25. https://doi.org/10.1212/wnl.0000000000002790
- 131Contraceptive Choices for Women with Inflammatory Bowel Disease. J Fam Plan Reprod Health. 2003; 29(3): 127. https://doi.org/10.1783/147118903101197782
- 132Perez-Aytes A, Ledo A, Boso V, Sáenz P, Roma E, Poveda JL, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008; 146A(1): 1–7. https://doi.org/10.1002/ajmg.a.32117
- 133Maddox DD, Rahman Z. Etonogestrel (Implanon), another treatment option for contraception. Pharm Therap. 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683610/#__ffn_sectitle
- 134Gromnica-Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol. 2010. http://europepmc.org/article/med/21044438
- 135Formulary BN. Rituximab. Rituximab. 2020. https://bnf.nice.org.uk/interaction/rituximab-2.html
Citing Literature
